Yubo International Biotech Ltd — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Yubo International Biotech Ltd filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.4K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $3.5K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $604.7K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $104.3K | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | $1.24M | Apr 14, 2023 |
| FY2020 | Feb 29, 2020 | $0 | Jun 25, 2020 |
| FY2020 | Feb 28, 2019 | $0 | Jun 25, 2020 |
| FY2019 | Feb 28, 2018 | $0 | Jun 12, 2019 |
| FY2018 | Feb 28, 2017 | $0 | Jun 13, 2018 |
| FY2017 | Feb 29, 2016 | $0 | Jun 14, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.2K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $2.6K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $419.2K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $52.7K | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | $820.6K | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $1.24M | Apr 15, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.08M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($1.78M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($1.20M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($1.20M) | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | ($1.54M) | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | ($711.8K) | Apr 15, 2022 |
| FY2020 | Feb 29, 2020 | ($134.0K) | Jun 25, 2020 |
| FY2020 | Feb 28, 2019 | ($148.0K) | Jun 25, 2020 |
| FY2019 | Feb 28, 2018 | ($144.0K) | Jun 12, 2019 |
| FY2018 | Feb 28, 2017 | ($224.0K) | Jun 13, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.19M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($1.77M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($1.19M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($1.21M) | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | ($1.54M) | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | ($711.8K) | Apr 15, 2022 |
| FY2020 | Feb 29, 2020 | ($29.0K) | Jun 25, 2020 |
| FY2020 | Feb 28, 2019 | ($48.0K) | Jun 25, 2020 |
| FY2019 | Feb 28, 2018 | ($58.0K) | Jun 12, 2019 |
| FY2018 | Feb 28, 2017 | ($149.0K) | Jun 13, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Feb 29, 2020 | $29.0K | Jun 25, 2020 |
| FY2020 | Feb 28, 2019 | $48.0K | Jun 25, 2020 |
| FY2019 | Feb 28, 2018 | $58.0K | Jun 12, 2019 |
| FY2018 | Feb 28, 2017 | $149.0K | Jun 13, 2018 |
| FY2017 | Feb 29, 2016 | $63.0K | Jun 14, 2017 |
| FY2016 | Feb 28, 2015 | $58.0K | Jun 10, 2016 |
| FY2015 | Feb 28, 2014 | $55.0K | Jun 15, 2015 |
| FY2014 | Feb 28, 2013 | $60.0K | Jun 6, 2014 |
| FY2012 | Feb 29, 2012 | $47.0K | Jun 12, 2013 |
| FY2011 | Feb 28, 2012 | $47.0K | Jun 11, 2012 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($842.8K) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($1.34M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($739.0K) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($601.0K) | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | ($1.02M) | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $101.1K | Apr 15, 2022 |
| FY2020 | Feb 29, 2020 | ($22.0K) | Jun 25, 2020 |
| FY2020 | Feb 28, 2019 | ($32.0K) | Jun 25, 2020 |
| FY2019 | Feb 28, 2018 | ($55.0K) | Jun 12, 2019 |
| FY2018 | Feb 28, 2017 | ($55.0K) | Jun 13, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $0 | Apr 14, 2023 |
| FY2022 | Dec 31, 2021 | $564.7K | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $42.6K | Apr 15, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $847.1K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $1.53M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $1.67M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $2.35M | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | $4.59M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $2.44M | Apr 15, 2022 |
| FY2020 | Feb 29, 2020 | $1.0K | Jun 25, 2020 |
| FY2020 | Feb 28, 2019 | $4.0K | Jun 25, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.79M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $4.83M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $3.51M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $2.91M | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | $4.72M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $1.28M | Apr 15, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.95M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($3.42M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($1.84M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($565.4K) | Apr 12, 2024 |
| FY2023 | Dec 31, 2021 | ($131.2K) | Apr 12, 2024 |
| FY2022 | Dec 31, 2020 | $1.17M | Apr 14, 2023 |
| FY2020 | Feb 29, 2020 | ($1.80M) | Jun 25, 2020 |
| FY2021 | Dec 31, 2019 | $488.7K | Apr 15, 2022 |
| FY2020 | Feb 28, 2019 | ($1.66M) | Jun 25, 2020 |
| FY2020 | Feb 28, 2018 | ($1.52M) | Jun 25, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.74M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($6.66M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($4.89M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($3.69M) | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | ($2.49M) | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | ($943.0K) | Apr 15, 2022 |
| FY2020 | Feb 29, 2020 | ($29.09M) | Jun 25, 2020 |
| FY2020 | Feb 28, 2019 | ($28.96M) | Jun 25, 2020 |
| FY2019 | Feb 28, 2018 | ($28.81M) | Jun 12, 2019 |
| FY2018 | Feb 28, 2017 | ($28.66M) | Jun 13, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.1K | Mar 31, 2026 |
| FY2024 | Dec 31, 2024 | $7.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2023 | $6.4K | Apr 12, 2024 |
| FY2022 | Dec 31, 2022 | $18.2K | Apr 14, 2023 |
| FY2021 | Dec 31, 2021 | $27.5K | Apr 15, 2022 |
| FY2021 | Dec 31, 2020 | $1.38M | Apr 15, 2022 |
| FY2020 | Feb 29, 2020 | $1.0K | Jun 25, 2020 |
| FY2021 | Dec 31, 2019 | $1.3K | Apr 15, 2022 |
| FY2020 | Feb 28, 2019 | $4.0K | Jun 25, 2020 |
| FY2020 | Feb 28, 2018 | $2.0K | Jun 25, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |